Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment.

Autor:	Londres HD; Julio Trigo Hospital, Havana, Cuba., Armada JJ; Salvador Allende Hospital, Havana, Cuba., Martínez AH; Julio Trigo Hospital, Havana, Cuba., Abdo Cuza AA; Medical & Surgical Research Center (CIMEQ), Havana, Cuba., Sánchez YH; Salvador Allende Hospital, Havana, Cuba., Rodríguez AG; Salvador Allende Hospital, Havana, Cuba., Figueroa SS; Julio Trigo Hospital, Havana, Cuba., Llanez Gregorich EM; Julio Trigo Hospital, Havana, Cuba., Torres Lahera ML; Julio Trigo Hospital, Havana, Cuba., Peire FG; Medical & Surgical Research Center (CIMEQ), Havana, Cuba., González TM; Luis Díaz Soto Hospital, Havana, Cuba., González YZ; National Institute of Hematology & Immunology, Havana, Cuba., Añé Kouri AL; Center of Molecular Immunology (CIM), Havana, Cuba., Palomo AG; Center of Molecular Immunology (CIM), Havana, Cuba., Concepción MT; Center of Molecular Immunology (CIM), Havana, Cuba., Pérez LM; Center of Molecular Immunology (CIM), Havana, Cuba., Luaces-Alvarez PL; Center of Molecular Immunology (CIM), Havana, Cuba., Iglesias DE; Center of Molecular Immunology (CIM), Havana, Cuba., Hernández DS; Center of Molecular Immunology (CIM), Havana, Cuba., Suzarte MR; Center of Molecular Immunology (CIM), Havana, Cuba., Ramos TC; Center of Molecular Immunology (CIM), Havana, Cuba.
Jazyk:	angličtina
Zdroj:	Immunotherapy [Immunotherapy] 2022 May; Vol. 14 (7), pp. 521-530. Date of Electronic Publication: 2022 Mar 21.
DOI:	10.2217/imt-2022-0027
Abstrakt:	Background: Lung injury and STAT1 deficit induce EGFR overexpression in SARS-CoV-2 infection. Patients & methods: A phase I/II trial was done to evaluate the safety and preliminary effect of nimotuzumab, an anti-EGFR antibody, in COVID-19 patients. Patients received from one to three infusions together with other drugs included in the national guideline. Results: 41 patients (31 severe and 10 moderate) received nimotuzumab. The median age was 62 years and the main comorbidities were hypertension, diabetes and cardiovascular disease. The antibody was very safe and the 14-day recovery rate was 82.9%. Inflammatory markers decreased over time. Patients did not show signs of fibrosis. Conclusion: Nimotuzumab is a safe antibody that might reduce inflammation and prevent fibrosis in severe and moderate COVID-19 patients. Clinical Trial Registration: RPCEC00000369 (rpcec.sld.cu).
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu